RRRenata Bezerra de Albuquerque Cavalcante Reis

Renata Bezerra de Albuquerque Cavalcante Reis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Renata Bezerra de Albuquerque Cavalcante Reis has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    miRNA-195 expression in the tumor tissues of female Brazilian breast cancer patients with operable disease

    by Alexandre Cesar Vieira de Sales, Isaura Isabelle Fonseca Gomes da Silva, Matheus Carvalho Brito Leite, Leandro de Lima Coutinho, Renata Bezerra de Albuquerque Cavalcante Reis, Danyelly Bruneska Gondin Martins, José Luiz de Lima Filho, Fabrício Oliveira Souto

    This study aimed to assess miRNA-195 expression in the tumor tissues from a cohort of Brazilian female breast cancer patients undergoing neoadjuvant chemotherapy (NAC) and evaluate its correlation with various clinicopathological markers.Quantitative ...


  • Open Access

    Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy

    by Alexandre Cesar Vieira Sales, Isaura Isabelle Fonseca Gomes da Silva, Matheus Cb Leite, Leandro L Coutinho, Renata Bac Reis, Angela Castoldi, Danyelly Bg Martins, José Luiz Lima-Filho, Fabricio Oliveira Souto

    Introduction: MicroRNA-21 (miRNA-21) has been described as one of the most significantly upregulated miRNAs in human breast cancer. However, limited knowledge exists on miRNA-21 expression in breast cancer tissue after neoadjuvant chemotherapy (NAC). Purpose: The aim of this study was to assess miRNA-21 expression in the tumor tissues of Brazilian patients with breast cancer who underwent NAC and its correlation with clinicopathological variables. Patients and Methods: Utilizing qRT-PCR, miRNA-21 expression in tumor tissue was measured in a cohort of female patients with breast cancer who underwent NAC. The correlation of miRNA-21 expression with breast cancer molecular subtypes and other clinicopathological variables was also assessed. Results: A total of 55 patients were included in the study, and 28 (50.9%) underwent NAC. miRNA-21 was upregulated in patients with breast cancer, regardless of previous exposure to chemotherapy, molecular subtypes, tumor-node-metastasis (TNM) staging and lymph node status of the axilla. miRNA-21 expression did not differ between patients with breast cancer who achieved a pathologic complete response after NAC and healthy controls. Conclusion: miRNA-21 was upregulated in the tumor tissue of Brazilian patients with breast cancer regardless of NAC treatment, which reinforces its role as an “oncomiR” and a potential biomarker.